GlassScriptPhysician profile
Keith V Preis
NPI 1750317301
$36,383.44
in general payments reported to CMS, 2019-2025
80 companies · $7,324 in 2025
The $7,324 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,414 · 2020: $3,410 · 2021: $4,705 · 2022: $5,385 · 2023: $5,474 · 2024: $6,673 · 2025: $7,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Education: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,075.72 |
| Education | $394.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $6,740.61 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $4,211.36 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,437.96 | 2020-2025 | Zeposia |
| Celgene Corporation | $2,342.20 | 2020-2025 | Zeposia |
| Ucb, INC. | $1,901.42 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Biogen, INC. | $1,763.37 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Teva Pharmaceuticals USA, INC. | $1,639.71 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $1,052.14 | 2022-2025 | Sunosi, Auvelity |
| Pfizer INC. | $857.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $716.64 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $664.03 | 2022-2025 | Purified Cortrophin Gel |
| Amgen INC. | $602.86 | 2019-2025 | Uplizna |
| Jazz Pharmaceuticals INC. | $594.03 | 2020-2025 | Xywav, Epidiolex |
| Lilly USA, LLC | $583.89 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Avanir Pharmaceuticals, INC. | $516.70 | 2019-2022 |
Show all 80 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Preis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.